Financial Results for the Nine Months Ended September 30, 2026
Filed with TSE · · 55 pages · English
Modalis Therapeutics Corporation on 6ix
In the deck
Story so far
Earlier from Modalis Therapeutics
- Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
- (Correction) Regarding Corrections to the "Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]"
- Business Plans and Matters Related to Growth Potential
- Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
- Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
Follow Modalis Therapeutics into a list and get an email when it puts out news.
Follow Modalis Therapeutics